guest ::
| Home > Institute Collections > W500 > A Division of Labor between YAP and TAZ in Non-Small Cell Lung Cancer. |
| Home > Institute Collections > W500 > A Division of Labor between YAP and TAZ in Non-Small Cell Lung Cancer. |
| Journal Article | DKFZ-2025-02395 |
; ; ; ; ; ; ; ; ;
2020
AACR
Philadelphia, Pa.
Abstract: Lung cancer is the leading cause of cancer-related deaths worldwide. The paralogous transcriptional cofactors Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ, also called WWTR1), the main downstream effectors of the Hippo signal transduction pathway, are emerging as pivotal determinants of malignancy in lung cancer. Traditionally, studies have tended to consider YAP and TAZ as functionally redundant transcriptional cofactors with similar biological impact. However, there is growing evidence that each of them also possesses distinct attributes. Here we sought to systematically characterize the division of labor between YAP and TAZ in non-small cell lung cancer (NSCLC), the most common histological subtype of lung cancer. Representative NSCLC cell lines as well as patient-derived data showed that the two paralogs orchestrated nonoverlapping transcriptional programs in this cancer type. YAP preferentially regulated gene sets associated with cell division and cell-cycle progression, whereas TAZ preferentially regulated genes associated with extracellular matrix organization. Depletion of YAP resulted in growth arrest, whereas its overexpression promoted cell proliferation. Likewise, depletion of TAZ compromised cell migration, whereas its overexpression enhanced migration. The differential effects of YAP and TAZ on key cellular processes were also associated with differential response to anticancer therapies. Uncovering the different activities and downstream effects of YAP and TAZ may thus facilitate better stratification of patients with lung cancer for anticancer therapies. SIGNIFICANCE: Thease findings show that oncogenic paralogs YAP and TAZ have distinct roles in NSCLC and are associated with differential response to anticancer drugs, knowledge that may assist lung cancer therapy decisions.
Keyword(s): Adaptor Proteins, Signal Transducing: genetics (MeSH) ; Adaptor Proteins, Signal Transducing: metabolism (MeSH) ; Carcinoma, Non-Small-Cell Lung: drug therapy (MeSH) ; Carcinoma, Non-Small-Cell Lung: metabolism (MeSH) ; Carcinoma, Non-Small-Cell Lung: pathology (MeSH) ; Cell Cycle: physiology (MeSH) ; Cell Line, Tumor (MeSH) ; Cell Movement (MeSH) ; Chromatin: genetics (MeSH) ; Chromatin: metabolism (MeSH) ; Gene Expression Regulation, Neoplastic (MeSH) ; Humans (MeSH) ; Lung Neoplasms: drug therapy (MeSH) ; Lung Neoplasms: metabolism (MeSH) ; Lung Neoplasms: pathology (MeSH) ; Paclitaxel: pharmacology (MeSH) ; Trans-Activators: genetics (MeSH) ; Trans-Activators: metabolism (MeSH) ; Transcription Factors: genetics (MeSH) ; Transcription Factors: metabolism (MeSH) ; Transcriptional Coactivator with PDZ-Binding Motif Proteins (MeSH) ; YAP-Signaling Proteins (MeSH) ; Adaptor Proteins, Signal Transducing ; Chromatin ; Trans-Activators ; Transcription Factors ; Transcriptional Coactivator with PDZ-Binding Motif Proteins ; WWTR1 protein, human ; YAP-Signaling Proteins ; YAP1 protein, human ; Paclitaxel
; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Current Contents - Life Sciences ; Ebsco Academic Search ; Essential Science Indicators ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
|
The record appears in these collections: |
